Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a methodological paper proposing and demonstrating a new evaluation framework for LLMs in safety-critical domains, not a clinical trial or empirical validation of a therapeutic or diagnostic intervention; it raises questions about LLM safety assessment rather than answering clinical questions.
This is a first methodological contribution introducing diagnostic metrics and an augmented architecture for latent world models in MPC planning, with experiments showing improved convergence and success rates, but lacking peer review and evaluation on established benchmarks.
Pharmacovigilance analysis of 2,486 real-world adverse event reports confirming known safety differences between drug classes with clear disproportionality signals, but observational and hypothesis-generating rather than practice-changing in design.
Preclinical mechanistic study with in vitro and in vivo experiments identifying a putative target and lead inhibitor, lacking clinical efficacy or safety data in humans.